| PARTNERING |
TR Pipeline
| Product Candidate |
Indications |
Development Stage |
Reference |
|
| Nasal granisetron |
Prevention of nausea and vomiting |
Phase 2 (US) |
(Phase1 results, graph) |
|
| Nasal triptan |
Treatment of migraine |
Pre-clinical |
|
|
Others
(insulin, morphine, fentanyl, etc) |
|
Pre-clinical
/ Feasibility research |
|
|
|
Other Candidates
|
Vaccines: flu vaccine, SARS vaccine, AIDS vaccine, etc.
Peptides: PTH(1-34), desmopressin, Gn-RH analog, etc. |
|
Device
|
Translational Reseach Division (TR) is further refining the Fit-lizer® device and developing new devices. |
|
| Licensing Opportunities |
|
TR's product candidates are available for out-licencing. Additionally,
 is applicable to a wide range of existing drugs and new compounds that
are targeted for nasal delivery. TR seeks to develop strong relationships
with pharmaceutical companies through out-licencing or collaboration using
.
|
|
|
|
|
